The U.S. Food and Drug Administration (FDA) has updated the label information for the commonly used anti-clotting medication Plavix® (clopidogrel) to stress to physicians that patients carrying certain genetic variations may not receive the full benefit from the drug.
Plavix reduces the chance a harmful clot will develop by preventing blood cells called platelets from sticking [...]

Tags: black box, boxed warning, clopidogrel, CYP2C19, Effient, FDA, metabolizer, Plavix, prasugrel

Medco Health Solutions, Inc., announced this week that it will conduct a clinical trial to assess whether clopidogrel bisulfate (Plavix®, Bristol-Myers Squibb and Sanofi-aventis) is just as effective as the newer drug prasugrel (Effient™, Eli Lilly and Company) in people who lack a genetic variation that inhibits their metabolism of clopidogrel. This new research has [...]

Tags: clopidogrel, clotting, comparative effectiveness research, CYP2C19, Effient, Francis Collins, heart, Medco, pharmacogenomics, Plavix, prasugrel